-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Pharmaceutical Guanlan
Recently, Magpie Medicine's Class 1 new drug nitroxazine for the treatment of amyotrophic lateral sclerosis (ALS) has obtained the implied approval of the US FDA clinical trial, and a phase 1 clinical bridging trial will be launched in the United States
Founded in 2011, Magpie Medicine is a clinical-stage company focusing on the research and development of innovative treatments for cardiovascular and mitochondrial diseases
Nitrazine is a class 1 chemical innovation drug exclusively transferred from Jinan University by Magpie Medicine, and it has a unique mechanism of action
In China, nitroxazine tablets are currently undergoing a phase 2 clinical study for the treatment of ALS, aiming to evaluate the efficacy, safety and PK characteristics of nitroxazine tablets in ALS patients
Amyotrophic lateral sclerosis, commonly known as "gradual freezing syndrome", is a fatal neurodegenerative disease characterized by the progressive degeneration of brain and spinal cord motor neurons
Note: The original text has been deleted
Reference materials:
[1] Magpie Medicine's class 1 chemical innovative drug for treatment of amyotrophic lateral sclerosis, nitroxazine tablets, was approved by the US FDA for clinical trials.